Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum

We report a new biomarker of hepatocarcinoma, vasorin (VASN), screened by a subtractive EMSA-SELEX strategy from AFP negative serum of hepatocellular carcinoma (HCC) patients with extrahepatic metastases. VASN was verified to be highly expressed in sera of 100 cases of HCC patients compared with 97...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Shaohua, Li, Hui, Yang, Xiqin, Wang, Wei, Huang, Aixue, Li, Jie, Qin, Xingliang, Li, Fei, Lu, Guanyi, Ding, Hongmei, Su, Xueting, Hou, Lvbin, Xia, Wei, Shi, Ming, Zhang, Hongwen, Zhao, Qiang, Dong, Jie, Ge, Xingfeng, Sun, Leqiao, Bai, Chenjun, Wang, Chaonan, Shen, Xuelian, Fang, Tao, Wang, Fusheng, Zhang, Heqiu, Shao, Ningsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496339/
https://www.ncbi.nlm.nih.gov/pubmed/25826090

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4496339/
https://www.ncbi.nlm.nih.gov/pubmed/25826090

Ejemplares similares